NCT06477653
- Conditions
- Eosinophilia, Hematologic Diseases, Hemic and Lymphatic Diseases, +2 more
- Locations
-
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
Clinical trial condition
Hypereosinophilic Syndrome
Explore clinical trials studying Hypereosinophilic Syndrome. Study availability and eligibility vary by location and protocol.
20 public trials
5 recruiting studies
Hypereosinophilic Syndrome trial results
NCT00091871
- Conditions
- Eosinophilia, Hematologic Diseases, Hemic and Lymphatic Diseases, +2 more
- Locations
-
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
NCT04018118
- Conditions
- Eosinophilia, Hematologic Diseases, Hemic and Lymphatic Diseases, +2 more
- Locations
-
- Hôpital Roger Salengro, CHU Lille, France
Recruiting
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
NCT03801434
- Conditions
- BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, +17 more
- Locations
-
- Stanford Cancer Institute Palo Alto Palo Alto, California, United States
- OHSU Knight Cancer Institute Portland, Oregon, United States
- University of Utah Salt Lake City, Utah, United States
- Fred Hutchinson cancer research center Seattle, Washington, United States
NCT05334368
- Conditions
- Eosinophilia, Hematologic Diseases, Hemic and Lymphatic Diseases, +2 more
- Locations
-
- GSK Investigational Site San Diego, California, United States
- GSK Investigational Site Atlanta, Georgia, United States
- GSK Investigational Site Boston, Massachusetts, United States
- GSK Investigational Site Southfield, Michigan, United States
Active, not recruiting
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
NCT04191304
- Conditions
- Eosinophilia, Hematologic Diseases, Hemic and Lymphatic Diseases, +2 more
- Locations
-
- Research Site La Jolla, California, United States
- Research Site Atlanta, Georgia, United States
- Research Site Bethesda, Maryland, United States
- Research Site Ann Arbor, Michigan, United States
Active, not recruiting
Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
NCT00044304
- Conditions
- Eosinophilia, Eosinophilic Myeloid Neoplasm, Hematologic Diseases, +3 more
- Locations
-
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
NCT04965636
- Conditions
- Eosinophilia, Hematologic Diseases, Hemic and Lymphatic Diseases, +2 more
- Locations
-
- GSK Investigational Site Rochester, Minnesota, United States
- GSK Investigational Site Cincinnati, Ohio, United States
- GSK Investigational Site Cleveland, Ohio, United States
- GSK Investigational Site Charleston, South Carolina, United States
Completed
Eosinophilia Diagnosis
NCT02581514
- Conditions
- Eosinophilia, Hematologic Diseases, Hemic and Lymphatic Diseases, +2 more
- Locations
-
- Médecine Interne A Limoges, France
NCT01713504
- Conditions
- Eosinophilia, Hematologic Diseases, Hemic and Lymphatic Diseases, +2 more
- Locations
-
- CHRU, Hôpital Claude Huriez Lille, Nord, France